Lifevantage Corp
LFVN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LFVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LFVN
Lifevantage Corp is a science-based nutraceutical company focused on health and wellness products, including its new patent-pending MindBody GLP-1 System for weight management, with cash and equivalents of $14.9M and shareholders' equity of $33.6M as of June 30, 2026.
Key risk: Working capital decline
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$80.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Lifevantage Corp is a science-based nutraceutical company focused on health and wellness products, including its new patent-pending MindBody GLP-1 System for weight management, with cash and equivalents of $14.9M and shareholders' equity of $33.6M as of June 30, 2026.
- Cash and equivalents of $14.9M and shareholders' equity of $33.6M as of 2026-06-30 [sec].
- Working capital of $18.1M as of June 30, 2026, down from $23.7M a year earlier [sec_mda · as of 2026-08-27].
- Launched patent-pending MindBody GLP-1 System designed to support weight management and wellness by activating GLP-1 [sec · filed 2025-09-19].
- Company believes cash and cash equivalents and ongoing cash flow from operations will be sufficient for at least the next 12 months [sec_mda · as of 2026-08-27].
- Capital allocation strategy follows a balanced approach focused on reinvestment, quarterly dividends, and opportunistic share repurchases [sec_mda · as of 2026-08-27].
What works
- Company has a patent-pending product (MindBody GLP-1 System) targeting the growing weight management market [sec · filed 2025-09-19].
- Positive working capital of $18.1M and shareholders' equity of $33.6M provide a solid financial base [sec_mda · as of 2026-08-27] [sec].
- Management expresses confidence that existing cash and operating cash flow will cover needs for at least 12 months [sec_mda · as of 2026-08-27].
What to weigh
- Working capital decreased from $23.7M to $18.1M year-over-year, driven by lower cash, inventory, and higher accounts payable [sec_mda · as of 2026-08-27].
- The company operates in a competitive nutraceutical market and must continuously manage dilution and equity compensation to retain talent [sec · filed 2025-09-19].
- No recent revenue or net income figures are provided in the available data, making it difficult to assess operational performance.
From the filings
Quoted directly from source documents.
Launch of patent-pending MindBody GLP-1 System
“launch of our new patent-pending MindBody GLP-1 System ™ designed to support weight management and wellness by activating GLP-1 n”
SEC filings · September 19, 2025
Working capital of $18.1M as of June 30, 2026
“At June 30, 2026, we had working capital (current assets minus current liabilities) of $18.1 million compared to working capital of $23.7 million at June 30, 2025.”
SEC MD&A · August 27, 2026
Company believes cash sufficient for at least 12 months
“We believe that our cash and cash equivalents balances and our ongoing cash flow from operations will be sufficient to satisfy our cash requirements for at least the next 12 months.”
SEC MD&A · August 27, 2026
Catalyst timeline
- 2024-01-30 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
- 2024-05-02 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
- 2024-08-28 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
- 2024-10-29 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
- 2025-02-05 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
- 2025-05-06 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
- 2025-09-04 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
- 2025-11-04 · Earnings Report — Quarterly earnings release via SEC 8-K filing.
Risks & what to watch (3)›
Key risks
- Working capital decline — Working capital fell from $23.7M to $18.1M year-over-year, indicating potential liquidity pressure [sec_mda · as of 2026-08-27].
- Competitive talent retention — Must use equity incentives to compete for talent, which can cause dilution [sec · filed 2025-09-19].
- No recent revenue data — Available filings do not disclose recent revenue or net income, limiting visibility into operating trends.
What to watch
- Future quarterly earnings reports for revenue and net income trends [catalyst].
- Adoption and sales performance of the MindBody GLP-1 System [sec · filed 2025-09-19].
- Changes in working capital and cash position in upcoming filings [sec_mda · as of 2026-08-27].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Lifevantage Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lifevantage Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.85
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 1 sell (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
104
Total value held
$35.1M
| Holder | Shares | Value |
|---|---|---|
| capital management corp /va | 2,441,919 | $10.5M |
| renaissance technologies llc | 867,704 | $3.7M |
| vanguard capital management llc | 858,844 | $3.7M |
| blackrock, inc. | 769,698 | $3.3M |
| dimensional fund advisors lp | 276,196 | $1.2M |
| geode capital management, llc | 261,192 | $1.1M |
| envestnet asset management inc | 219,162 | $947K |
| goldman sachs group inc | 185,114 | $800K |
| state street corp | 167,143 | $722K |
| aqr capital management llc | 156,096 | $674K |
Showing top 10 of 104 institutional holders of Lifevantage Corp. Open the full 13F history after sign-in.
Short Interest
as of May 13, 2026- % of float
- 38.6%
- Days to cover
- 21.6
- Shares short
- 3,853,011
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LFVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lifevantage Corp?
Lifevantage Corp is a science-based nutraceutical company focused on health and wellness products, including its new patent-pending MindBody GLP-1 System for weight management, with cash and equivalents of $14.9M and shareholders' equity of $33.6M as of June 30, 2026.
Who is the CEO of Lifevantage Corp?
Mr. Terrence O. Moorehead is the chief executive officer of Lifevantage Corp (LFVN).
Where is Lifevantage Corp headquartered?
Lifevantage Corp (LFVN) is headquartered in Lehi, UT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.